ストックスクリーナーアプリを入手
18.27
0.33%
0.06
アフターアワーズ：
18.27
前日終値:
$18.21
開ける：
$18.23
24時間の取引高:
353.71K
Relative Volume:
0.42
時価総額：
$2.06B
収益：
$454.68M
当期純損益:
$-178.68M
株価収益率:
-11.27
EPS:
-1.6209
ネットキャッシュフロー:
$-135.66M
1週間 パフォーマンス:
-4.94%
1か月 パフォーマンス:
-3.84%
6か月 パフォーマンス:
+10.06%
1年 パフォーマンス:
-51.67%
1日の値動き範囲:
$17.97
$18.77
1週間の範囲:
$17.92
$19.31
52週間の値動き範囲:
$15.96
$39.64
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Compare ZLAB vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
18.27 | 2.10B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-14 | 開始されました | Morgan Stanley | Overweight |
| 2023-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 開始されました | Macquarie | Outperform |
| 2021-10-12 | 開始されました | Bernstein | Mkt Perform |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-04-15 | 開始されました | Guggenheim | Buy |
| 2019-07-12 | 開始されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
| 2019-01-29 | 開始されました | Credit Suisse | Outperform |
| 2018-11-21 | 開始されました | Jefferies | Buy |
| 2018-06-21 | 再開されました | Leerink Partners | Outperform |
| 2018-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 開始されました | JP Morgan | Neutral |
| 2017-10-16 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Zai Lab Limited Adr (ZLAB) 最新ニュース
ZLAB|Zai Lab Ltd|Price:19.080|Chg%:-0.140 - TradingKey
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
A2DX1V Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 - BioSpace
Zai Lab schedules an Aug. 6 webcast and call for Q2 results - Stock Titan
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Zai Lab and Boehringer Advance New Immunotherapy Combo in Small Cell Lung Cancer - TipRanks
Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) CEO Du Ying gains ADSs from RSU awards and tax withholding - Stock Titan
ZLABZai Lab Limited ADR Options - Finviz
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - MSN
Zai Lab stock keeps its listing focus. Investors watch the US ADR profile. - Ad-hoc-news.de
Zai Lab (ZLAB) CEO sells ADS to cover taxes after RSU vesting - Stock Titan
Form 144 Zai Lab Ltd For: 30 June By Investing.com - Investing.com Nigeria
ZLAB (NASDAQ: ZLAB) insider resale planned on 06/29/2026; recent ADS sales reported - Stock Titan
Zai Lab (ZLAB) legal chief settles RSUs, sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CEO sells ADSs after RSU vesting and tax cover - Stock Titan
CFO equity transactions at Zai Lab (ZLAB) show RSU vesting and tax sale - Stock Titan
Zai Lab ADR outlines oncology pipeline priorities, shares tied to upcoming data - ad-hoc-news.de
1ZL Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (GETTEX:1ZL) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (LS:A2DX1V) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ZLAB) - TradingView
Form 144 Zai Lab Ltd For: 26 June - Investing.com South Africa
Form 144 Zai Lab Ltd For: 26 June By Investing.com - Investing.com Nigeria
ZLAB (NASDAQ) director files to sell 2,264 ADS after vesting - Stock Titan
ZLAB (NASDAQ: ZLAB) director files Form 144 to sell 4,103 ADS on vesting - Stock Titan
ZLAB (NASDAQ: ZLAB) Form 144 shows Ying Du ADS sales and vesting event - Stock Titan
ZLAB/N Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab (ZLAB) director Lis sells 7,040 ADS under 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS restricted share grant - Stock Titan
Director John D. Diekman receives 22,371 Zai Lab (ZLAB) ADS grant - Stock Titan
Zai Lab (ZLAB) director granted 22,371 restricted ADS vesting in 2027 - Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS stock award, now holds 79,001 ADSs - Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS restricted stock grant vesting 2027 - Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS equity award - Stock Titan
Form 144 Zai Lab Ltd For: 22 June By Investing.com - Investing.com Australia
[144] Zai Lab Ltd SEC Filing - Stock Titan
Why Zai Lab (ZLAB) Is Up 6.5% After Dual TIVDAK China Approval and EU Orphan Win – And What's Next - Sahm
Zai Lab Stockanalyst consensus and sector backdrop on a quiet news day - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) holders back pay and 10% share mandates - Stock Titan
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas - Business Wire
Number of shareholders of Zai Lab Ltd. Sponsored ADR – SWB:1ZL - TradingView
TCG Crossover funds, Chen Yu hold 5.3% of ZLAB (ADS positions) - Stock Titan
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB) - Sahm
Assessing Zai Lab (ZLAB) Valuation After China Approval Of TIVDAK For Advanced Cervical Cancer - Sahm
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - BioSpace
Trial's China arm: TIVDAK cuts death risk 45% vs chemo in cervical cancer - Stock Titan
(tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
Equity grants for Zai Lab (ZLAB) operating partner Wang Yizhe - Stock Titan
Zai Lab (ZLAB) Operating Partner Wang Yizhe listed as insider on Form 3 - Stock Titan
Zai Lab Limited Adr (ZLAB) 財務データ
収益
当期純利益
現金流量
EPS
Zai Lab Limited Adr (ZLAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Du Ying | Chairperson & CEO |
Jun 30 '26 |
Sale |
18.53 |
7,026 |
130,220 |
1,203,784 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):